

PEPTIDE-CARRIER Fusion Vaccines for Allergy Treatment



Next generation technology enables convenient and safe specific immunotherapy and prophylaxis . **now with PoC in phase IIb!!**

- Allergy immunotherapy platform with unrivaled efficacy and safety profile
- Potential for therapeutic and prophylactic immunization
- Dramatically improved dosing schedule
- Clinical proof of concept from phase II studies available for lead product BM32 (grass pollen allergy)
- Dose regimen optimization study ongoing
- Technology and IP open for out-licensing or co-development



PEPTIDE-CARRIER fusion molecules



Effect of PEPTIDE-CARRIER Fusion Vaccines

The technology is based on allergen derived peptides . B-cell epitopes of 20-30 amino acids . which are fused to an immunogenic carrier protein. The peptides are not IgE reactive (hypoallergenic). Immunization with the recombinant fusion protein effectively leads to a strong allergen specific (peptide mediated) IgG response, while the T-cell help is provided by the carrier. Due to the specific molecular design, a focused and highly protective immune response is achieved and strong allergic side effects are avoided.

The platform is broadly applicable to all allergies.

Pre-clinical results are available proving the unique efficacy and safety profile of the PEPTIDE-CARRIER fusion concept. A lead candidate vaccine BM32 against grass pollen allergy has been selected for clinical development.

A clinical phase I safety study, a phase IIa pollen chamber study and a phase IIb field trial with BM32 have been completed and have demonstrated impressive clinical efficacy. Optimization of dose regimen is underway. Molecule candidates for other major allergies including birch, house dust mite, ragweed and cat are in lead optimization and pre-clinical development.

Potential Revolution in Allergy Immunotherapy

Allergy vaccines derived from Biomay's PEPTIDE-CARRIER fusion platform are characterized by a unique efficacy and safety profile. Adverse side effects which prevent the broad application of current extract based immunotherapy, are overcome. This enables broad therapeutic and prophylactic application . potentially even by the general practitioner . thus offering a significant increase in the market potential of allergy immunotherapy.

Licensing Opportunity

The PEPTIDE-CARRIER fusion technology is broadly patent-protected. The whole platform package including vaccines for all important allergies, or single vaccines derived thereof including grass pollen vaccine (BM32), birch pollen vaccine (BM31), house dust mite vaccine (BM35), ragweed pollen vaccine (BM34) and cat dander (BM36) are available for out-licensing or co-development.

Additional Information

Focke et al. (2015) J Allergy Clin Immunol.;135:1207 | WO2007/140505 | EP1219299 | US7244431 WO2012/168487 EP2717910 US201515335735

Contact:

Rainer Henning, CEO | r.henning@biomay.com | t: +43 1 7966 296 100; m: +43 664 415 9511
Biomay AG | Vienna Competence Center | Lazarettgasse 19 | A-1090 Vienna

| allergy vaccines |

www.biomay.com